Size and usage patterns of private TB drug markets in the high burden countries

PLoS ONE

Volumn 6, Issue 5, 2011, Pages

  Wells, William A ^a   Ge, Colin Fan ^b   Patel, Nitin ^b   Oh, Teresa ^b   Gardiner, Elizabeth ^a   Kimerling, Michael E ^c  

^a GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^b IQVIA   (United States)

^c BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; KANAMYCIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG UTILIZATION; HEALTH CARE AVAILABILITY; HEALTH CARE POLICY; HEALTH PROGRAM; INDIA; INDONESIA; MULTIDRUG RESISTANT TUBERCULOSIS; PAKISTAN; PHILIPPINES; PRIVATE PRACTICE; TREATMENT OUTCOME; ECONOMICS; HUMAN; ORGANIZATION AND MANAGEMENT; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; HUMANS; INDIA; INDONESIA; PAKISTAN; PRIVATE SECTOR; PUBLIC SECTOR; TUBERCULOSIS;

EID: 79955753997     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018964     Document Type: Article

References (31)

1. WHO (2010) Global tuberculosis control: WHO report 2010 Geneva, Switzerland World Health Organization.
2. WHO (2009) Treatment of tuberculosis: Guidelines, 4th edition Geneva World Health Organization.
3. Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, et al. (2010) TB regimen change in the high burden countries. Int J Tuberc Lung Dis 14: 1538-1547.
4. Uplekar MW, Shepard DS, (1991) Treatment of tuberculosis by private general practitioners in India. Tubercle 72: 284-290.
5. Udwadia ZF, Pinto LM, Uplekar MW, (2010) Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLoS One 5: e12023.
6. Portero JL, Rubio M, (2003) Private practitioners and tuberculosis control in the Philippines: strangers when they meet? Trop Med Int Health 8: 329-335.
7. Jaggarajamma K, Balambal R, Muniyandi M, Vasantha M, Thomas B, et al. (2009) Perceptions of tuberculosis patients about private providers before and after implementation of Revised National Tuberculosis Control Programme. Indian J Tuberc 56: 185-190.
8. Uplekar M, (2003) Involving private health care providers in delivery of TB care: global strategy. Tuberculosis (Edinb) 83: 156-164.
9. WHO (2006) Engaging all health care providers in TB control: guidance on implementing public-private mix approaches Geneva World Health Organization.
10. Hopewell PC, Pai M, Maher D, Uplekar M, Raviglione MC, (2006) International standards for tuberculosis care. Lancet Infect Dis 6: 710-725.
11. Nathanson E, Nunn P, Uplekar M, Floyd K, Jaramillo E, et al. (2010) MDR tuberculosis-critical steps for prevention and control. N Engl J Med 363: 1050-1058.
12. Schwalbe NR, Wells WA, Geaneotes AP, Forcellina A, Lee MG, et al. (2008) Estimating the market for tuberculosis drugs in industrialized and developing nations. Int J Tuberc Lung Dis 12: 1173-1181.
13. TB Alliance (2007) Pathway to Patients: Charting the Dynamics of the Global TB Drug Market New York Global Alliance for TB Drug Development.
14. WHO (2009) Global tuberculosis control: epidemiology, strategy, financing Geneva, Switzerland World Health Organization.
15. WHO (2008) Guidelines for the programmatic management of drug-resistant tuberculosis Geneva World Health Organization.
16. Wang L, Cheng S, Xu M, Huang F, Xu W, et al. (2009) Model collaboration between hospitals and public health system to improve tuberculosis control in China. Int J Tuberc Lung Dis 13: 1486-1492.
17. Dewan PK, Lal SS, Lonnroth K, Wares F, Uplekar M, et al. (2006) Improving tuberculosis control through public-private collaboration in India: literature review. Bmj 332: 574-578.
18. Lonnroth K, Uplekar M, Blanc L, (2006) Hard gains through soft contracts: productive engagement of private providers in tuberculosis control. Bull World Health Organ 84: 876-883.
19. Lonnroth K, Uplekar M, Arora VK, Juvekar S, Lan NT, et al. (2004) Public-private mix for DOTS implementation: what makes it work? Bull World Health Organ 82: 580-586.
20. Mantala MJ, (2003) Public-private mix DOTS in the Philippines. Tuberculosis (Edinb) 83: 173-176.
21. Ahmed J, Ahmed M, Laghari A, Lohana W, Ali S, et al. (2009) Public private mix model in enhancing tuberculosis case detection in District Thatta, Sindh, Pakistan. J Pak Med Assoc 59: 82-86.
22. WHO (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response Geneva World Health Organization.
23. Wells WA, Konduri N, Chen C, Lee D, Ignatius HR, et al. (2011) Implications of the current TB treatment landscape for future regimen change. Int J Tuberc Lung Dis in press.
24. Uplekar M, Juvekar S, Morankar S, Rangan S, Nunn P, (1998) Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis 2: 324-329.
25. Pinto LM, Udwadia ZF, (2010) Private patient perceptions about a public programme; what do private Indian tuberculosis patients really feel about directly observed treatment? BMC Public Health 10: 357.
26. Quy HT, Lonnroth K, Lan NT, Buu TN, (2003) Treatment results among tuberculosis patients treated by private lung specialists involved in a public-private mix project in Vietnam. Int J Tuberc Lung Dis 7: 1139-1146.
27. Krishnan N, Ananthakrishnan R, Augustine S, Vijayalakshmi NK, Gopi PG, et al. (2009) Impact of advocacy on the tuberculosis management practices of private practitioners in Chennai City, India. Int J Tuberc Lung Dis 13: 112-118.
28. Ipuge YA, Rieder HL, Becx-Bleumink M, Kimerling ME, (1997) Evaluation and planning in national tuberculosis control programmes: the usefulness of the standardised patient treatment card. East Afr Med J 74: 816-818.
29. WHO (1999) Fixed-dose combination tablets for the treatment of tuberculosis. Report of an informal meeting held in Geneva, Tuesday 27 April 1999 Geneva World Health Organization.
30. Caminero JA, Sotgiu G, Zumla A, Migliori GB, (2010) Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 10: 621-629.
31. Agrawal D, Udwadia ZF, Rodriguez C, Mehta A, (2009) Increasing incidence of fluoroquinolone-resistant Mycobacterium tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 13: 79-83.